Factors Favoring Long Term Survival in Patients with Stage IV Epithelial Ovarian Cancer: An Institutional Research

Sarwar, Hafiz Abubakar; Iftikhar, Jhanzeb; Yasmeen, Samia; Sheikh, Fareeha; Ali, Fatima Bhopalwala; Syed, Aamir Ali; Siddiqui, Neelam

doi:10.31557/apjcc.2020.1.1.15-18

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported a 13.4% frequency of MOC among 544 EOC patients from our center. 15 To the best of our knowledge, this is the first study of primary mucinous ovarian cancer as a separate entity, from Pakistan.…”

Section: Discussionmentioning

confidence: 90%

Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan

Hamdani

Azhar

Wahab

et al. 2022

South Asian J Cancer

Self Cite

View full text Add to dashboard Cite

Objective To evaluate the clinicopathological features and survival outcomes of mucinous ovarian cancer (MOC) patients in an Asian population. Study Design Descriptive observational study. Place and Duration of Study Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan, from January 2001 to December 2016. Methods Data of MOC were evaluated for demographics, tumor stage, clinical characteristics, tumor markers, treatment modalities, and outcomes from electronic Hospital Information System. Results Nine-hundred patients with primary ovarian cancer were reviewed, out of which 94 patients (10.4%) had MOC. The median age was 36 ± 12.4 years. The most common presentation was abdominal distension 51 (54.3%), while the rest presented with abdominal pain and irregular menstruation. Using FIGO (The International Federation of Gynecology and Obstetrics) staging, 72 (76.6%) had stage I, 3 (3.2%) stage II, stage III in 12 (12.8%), and 7 (7.4%) had stage IV disease. The majority of patients 75 (79.8%) had early-stage (stage I/II), while 19 (20.2%) presented with advanced-stage (III & IV). The median follow-up duration was 52 months (range 1–199 months). Among patients with early-stage (I&II), 3- and 5-year progression-free survival (PFS) was 95%, while for advanced stage (III&IV), PFS was 16% and 8%, respectively. The overall survival (OS) in early-stage I&II was 97%, while for advanced stages III & IV, the OS was 26%. Conclusion MOC is a challenging and rare subtype of ovarian cancer requiring special attention and recognition. Most patients treated at our center presented with early stages and had excellent outcomes, while advanced-stage disease had dismal results.

show abstract

Section: Discussionmentioning

confidence: 90%

Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan

Hamdani

Azhar

Wahab

et al. 2022

South Asian J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ovarian Cancer (OC) has the highest mortality rate among gynecological malignancies. More than 150,000 people die every year worldwide (1). Because of its hidden dangers and the lack of early and effective diagnosis methods, 80% of patients are late for treatment.…”

Section: Introductionmentioning

confidence: 99%

MiR-145 on the Proliferation of Ovarian Cancer Cells by Regulating the Expression of MMP-2/MMP-9

Wang

Zhang

2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

This study aimed to consider the effect of miR-145 on the proliferation of OC cells by regulating the expression of MMP-2/MMP-9. In this experiment, the miR-145 target gene with restriction enzyme cut sites was amplified from the four groups of rat genomes, and it was ligated to the pIRES plasmid to form a recombinant plasmid and identified. The miR-145 recombinant plasmid and the empty plasmid into OC cells were transfected, and qRT-PCR was used to detect the expression of miR-145 in the transfected OC cells. Experimental data showed that there are a total of 60 healthy male SD rats, randomly divided into 4 groups, namely the normal saline control group (group A), the model group ( group B), treatment group with 30 mg miR-145 (group C), and treatment group with 100mg miR -145 (group D). The experimental results showed that compared with group A, the expression of MMP-2 protein in rats in groups B, C, and D all increased to varying degrees on 7 days, 14 days, and 28 days, reaching the highest at 14 days. This study shows that miRNA-145 is under-expressed in OC cell lines, and miR-145 can significantly inhibit the proliferation and invasion of ovarian cells by regulating the expression of MMP-2/MMP-9.

show abstract

Factors Favoring Long Term Survival in Patients with Stage IV Epithelial Ovarian Cancer: An Institutional Research

Cited by 2 publications

References 14 publications

Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan

Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan

MiR-145 on the Proliferation of Ovarian Cancer Cells by Regulating the Expression of MMP-2/MMP-9

Contact Info

Product

Resources

About